Drug Discovery Chemistry

San Diego, CA. First-generation cancer immunotherapy agents have been primarily biologicals — monoclonal antibodies that block protein-protein interactions between T cell checkpoint receptors and their ligands. Recently, discovery efforts have focused on the...

American Chemical Society National Meeting and Exposition

New Orleans, LA. Dr. Jian Wu, Associate Director at Progenra, presented a talk entitled ” Small molecules as frontline therapy for immune oncology: Experience from ubiquitin pathway targets ” at medicinal chemistry section. The ACS National Meeting brings...

Progenra Receives Second Immune Oncology Patent

MALVERN, PA, May 10, 2017 –(BUSINESS WIRE) — Progenra, Inc. announced that it has received the Official Notice of Allowance (dated March 30, 2017) of its patent application entitled “Methods of treating cancer through the inhibition of USP7 and immune...